Navigation Links
Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
Date:12/17/2008

MUMBAI, India, Dec. 17 /PRNewswire/ -- Pharma Major, Lupin Ltd. announced today that it has settled all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough's "Clarinex"(R) tablets.

As per the terms of the settlement, Lupin Ltd. will be licensed under the relevant Desloratadine patents, and free to commercially launch its generic Desloratadine product, on July 1, 2012, or earlier in certain circumstances.

Lupin had earlier filed a Paragraph IV certification to, among others, U.S. Patent Nos. 6,100,274, 7,214,683 and 7,214,684, contesting that these patents were either invalid or had not been infringed upon - resulting in the subsequent litigation by Schering Corp. and Sepracor.

Schering-Plough's Clarinex(R) tablets had U.S. sales of $329 million for the year 2007-MAT June 2008, according to IMS Health.

Commenting on the settlement, Dr. Kamal Sharma, Managing Director, Lupin said - "The settlement with Schering-Plough leaves us strategically poised to further strengthen, consolidate and grow our market position in the U.S. markets. Furthermore, the settlement, recent product approvals and growth in filings across markets are a testament to our increased strengths and focus on Research & Development and the quality of our Intellectual property - a testimony to Lupin's larger goal of developing and delivering quality, cost-effective drugs for everybody."

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Currently positioned amongst the top six pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders. For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US$ 694 million) and Rs.4,083 million (US$ 102 million), respectively.

    BSE : 500257    NSE: Lupin    REUTERS: LUPN.BO    BLOOMBERG:LPC IN

    For further information contact: 

    Shamsher Gorawara
    Head - Corporate Communications
    Lupin Limited
    Mobile: +91 9820338555
    shamshergorawara@lupinpharma.com 

    OR

    Archana Pradhan
    Escher PR
    Tel. +91 22 24901327, 24901328
    Mobile: +91 9820330505
    archana@escherpr.com


'/>"/>
SOURCE Lupin Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
2. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
3. Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
4. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
5. Lupin Launches Ramipril Capsules
6. Lupin Receives USFDA Approval for Topiramate Tablets
7. Dynatronics Announces Changes to Board and Launches Operational Improvement Process
8. SantaFe Senior Living Announces Leadership Transition
9. Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM
10. Finesse Announces TruDO Optical Autoclavable Sensors for Bioprocess Applications
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... ... welcoming new patients with periodontal plastic surgery treatments, including crown lengthening ... Dr. Green provides these esthetic and functional procedures to help patients improve their ...
(Date:5/22/2017)... ... 2017 , ... “Homeostasis: The Journey of a Manic-Depressive” tells the story in ... Rodriguez takes readers on a rollercoaster ride that includes a midnight trek to the ... a dark place where Donald considers suicide. Readers learn how Donald finally achieves ...
(Date:5/22/2017)... ... May 22, 2017 , ... WeightZone Factor a popular ... Factor members to track their exercise patterns, monitor behavioral changes, employ biometric monitoring, ... their mobile phones. It also provides social networks for members with similar interests ...
(Date:5/21/2017)... ... 19, 2017 , ... HealthSmart, the largest independent benefits administrator ... as Chief Information Officer (CIO). He will be joining HealthSmart at the end ... performance. He defines strategic roadmaps by reimagining business processes—bridging the gap between information ...
(Date:5/21/2017)... ... , ... Pot. Reefer. Grass. Mary Jane. No matter what people call it, ... never before. More than a map, new social marketplace Weedable goes beyond ... and for the first time – each other. A social marketplace like no other, ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 2017  The Corporate Whistleblower Center says, "We ... therapy clinics to call us anytime at 866-714-6466 if ... involved in a substantial scheme to overbill Medicare. ... an employee of a medical equipment company if ... provide medical practice groups with extra generous incentives to ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
(Date:5/9/2017)... -- Demonstrating its commitment to representing research- based biopharmaceutical ... Research and Manufacturers of America (PhRMA) today approved ... have to meet new research and development (R&D) ... PhRMA. "By putting in place new ... message that being a member of PhRMA means ...
Breaking Medicine Technology: